Table 4.
The distribution of JAK1 expression and clinicopathological variables in vitiligo patients
| Clinicopathological parameter | Focal (n = 21) | Diffuse (n = 18) | Statistical test | p-value |
|---|---|---|---|---|
| Age (yr) | ||||
| Mean ± SD | 36.43 ± 16.29 | 33.22 ± 13.71 | 0.17a | .860 |
| Median (range) | 33.00 (18–64) | 27.00 (21–55) | ||
| Disease duration (yr) | 2.16a | .030* | ||
| Mean ± SD | 6.29 ± 4.30 | 3.78 ± 1.98 | ||
| Median (range) | 4.00 (3–15) | 4.00 (2–7) | ||
| Sex | 4.88b | .020* | ||
| Male | 12 (57.1) | 4 (22.2) | ||
| Female | 9 (42.9) | 14 (77.8) | ||
| Onset (yr) | 0.21c | .650 | ||
| < 20 | 6 (28.6) | 4 (22.2) | ||
| ≥ 20 | 15 (71.4) | 14 (77.8) | ||
| Family history | ||||
| Negative | 12 (57.1) | 14 (77.8) | 1.85b | .170 |
| Positive | 9 (42.9) | 4 (22.2) | ||
| Distribution | ||||
| NSV | 6 (28.6) | 7 (38.9) | 0.46b | .490 |
| SV | 15 (71.4) | 11 (61.1) | ||
| Melanin | 0.01b | .920 | ||
| Absent | 12 (57.1) | 10 (55.6) | ||
| Present | 9 (42.9) | 8 (44.4) | ||
| Dermal inflammation | ||||
| Mild | 15 (71.4) | 11 (61.1) | 0.46b | .490 |
| Moderate | 6 (28.6) | 7 (38.9) | ||
| HMB45 status | 0.06b | .800 | ||
| Negative | 9 (42.9) | 7 (38.9) | ||
| Positive | 12 (57.1) | 11 (61.1) | ||
| HMB45 (%) | 3.42a | .001* | ||
| Mean ± SD | 30.90 ± 33.18 | 3.33 ± 4.85 | ||
| Median (range) | 15.00 (0–90) | 0 (0–10) |
JAK1, Janus kinase 1; SD, standard deviation; NSV, non-segmental vitiligo; SV, segmental vitiligo; HMB45, human melanoma black 45.
*
Significant.
a
Mann-Whitney test;
b
Chi-square test;
c
Fisher exact test.